FibroBiologics, Inc. 8-K/A

What Happened
FibroBiologics, Inc. (FBLG) filed an amended Form 8-K dated April 9, 2026 to include Item 1.01 (entry into a material definitive agreement) and also reported Item 1.02 (termination of a material definitive agreement). The company states the amendment was made solely to add Item 1.01 and that no other disclosure in the Original Report has changed. The filing also notifies investors that FibroBiologics’ principal executive offices have moved to 9350 Kirby Drive, Suite 300, Houston, Texas 77054. The report is signed by CEO Pete O'Heeron.

Key Details

• Filing date / signature: April 9, 2026; signed by Pete O'Heeron, Chief Executive Officer.
• Item changes: Amendment to earlier 8-K to include Item 1.01 (entry into a material definitive agreement); Item 1.02 reports termination of a material definitive agreement.
• New corporate address: 9350 Kirby Drive, Suite 300, Houston, Texas 77054 (principal executive offices).
• Administrative exhibit: Exhibit 104 (Cover Page Interactive Data File) included with the filing.

Why It Matters
Changes to material definitive agreements (entries or terminations) can affect the company’s contractual obligations and future operations; however, this filing does not provide the substantive terms or financial impact of those agreements. The address change affects where investor communications and official notices should be sent. Retail investors should review the Original Report and watch for subsequent filings or disclosures that provide full details on the specific agreements and any related financial effects.